Skip to main content

Table 1 Demographic and baseline clinical characteristics

From: Formoterol as reliever medication in asthma: a post-hoc analysis of the subgroup of the RELIEF study in East Asia

Characteristic

Formoterol

Salbutamol

All

(n = 1418)

(n = 1416)

(n = 2834)

Male

736 (51.9)

700 (49.4)

1436 (50.7)

Mean age, years (range)

35 (5–81)

36 (6–85)

35 (5–85)

Age groups

  Children ≤11 years

254 (17.9)

258 (18.2)

512 (18.1)

  Adolescents 12–17 years

121 (8.5)

111 (7.8)

232 (8.2)

  Adults 18–64 years

957 (67.5)

946 (66.8)

1903 (67.1)

  Elderly ≥65 years

86 (6.1)

101 (7.1)

187 (6.6)

Race

   

  Oriental

1397 (98.5)

1389 (98.1)

2786 (98.3)

  Caucasian

4 (0.3)

8 (0.6)

12 (0.4)

  Other

17 (1.2)

19 (1.3)

36 (1.3)

Asthma severity (judged by asthma medication level)*

  Intermittent

206 (14.5)

201 (14.2)

407 (14.4)

  Mild

740 (52.2)

713 (50.4)

1453 (51.3)

  Moderate

299 (21.1)

318 (22.5)

617 (21.8)

  Severe

173 (12.2)

184 (13.0)

357 (12.6)

Regular smoker

158 (11.1)

148 (10.5)

306 (10.8)

  1. Data are presented as n (%) patients, unless otherwise stated
  2. * Intermittent: no maintenance treatment; mild: inhaled corticosteroid (ICS) <500 μg/day (<400 μg/day in children) or a regular long-acting β2-agonist (LABA), cromone, theophylline or leukotriene modifier; moderate: ICS alone at any dose ≥500 μg/day (≥400 μg/day in children), or ICS 500–800 μg/day (400–800 μg/day in children) in combination with LABA, theophylline or leukotriene modifier; severe: ICS >800 μg/day in combination with LABA, theophylline, leukotriene modifier, or oral corticosteroids